mtor: receipt-backed evidence fronts

Source literature boundary memo

Research question

Across retrieved fact-level receipts for mtor, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

Selection criteria

The source-literature fallback selected mtor because the domain snapshot exposed enough fact-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Boundary map

• International consensus on post-transplantation diabetes mellitus [primary; 2024] doi:10.1093/ndt/gfad258
  • Finding: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10
  • Population: de novo kidney transplant recipients from 13 studies
  • Intervention/exposure: CNI plus mTOR inhibitors
  • Comparator: CNI plus antiproliferative agents
• mTOR inhibition improves immune function in the elderly [primary; 2014] doi:10.1126/scitranslmed.3009892
  • Finding: RAD001 improved influenza vaccine response by ~20% in the elderly
  • Population: elderly humans (≥65 years), n=218
  • Intervention/exposure: RAD001 (everolimus) 0.5 mg daily, 5 mg weekly, or 20 mg weekly for 6 weeks before vaccination
  • Comparator: placebo
• Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. [review; 2014] doi:10.1111/tri.12372
  • Finding: Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%)
  • Population: HCC liver transplant recipients
  • Intervention/exposure: mTOR inhibitors
  • Comparator: calcineurin inhibitors
• Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. [primary; 2013] doi:10.1016/j.celrep.2013.07.030
  • Finding: exhibit an approximately 20% increase in median survival.
  • Population: mice with hypomorphic mTOR alleles
  • Intervention/exposure: genetic reduction of mTOR expression
  • Comparator: wild-type mice
• Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis [primary; 2010] doi:10.1158/1940-6207.capr-10-0055
  • Finding: Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition of mTOR in tumors.
  • Population: A/J mice treated with tobacco carcinogen NNK
  • Intervention/exposure: intraperitoneal metformin

Source synthesis

This receipt-backed scoping note has one bounded signal: mtor shows context-dependent, not convergent, associations across this 5-source primary/review bundle (2010-2024). Grouped by direction, directionally favorable: RAD001 improved influenza vaccine response by ~20% in the elderly; Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition... | other/mixed: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P =...; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10; RAD001 improved influenza vaccine response by ~20% in the elderly; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%).

Directional grouping

• other/mixed: International consensus on post-transplantation diabetes mellitus — observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10
• directionally favorable: mTOR inhibition improves immune function in the elderly — RAD001 improved influenza vaccine response by ~20% in the elderly
• other/mixed: Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. — Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%)
• other/mixed: Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. — exhibit an approximately 20% increase in median survival.
• directionally favorable: Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis — Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition of mTOR in tumors.

Candidate moderators are population or indication, endpoint, comparator, and study design/evidence type; these dimensions explain why the receipts should be read as divergent evidence fronts, not one pooled effect.

Context separation

The selected receipts group because each carries a fact-level extraction for mtor; they separate by context (animal model, human clinical/observational, and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim.

Boundary limits

Source-literature boundary for mtor: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.

Next gaps

A stronger memo needs one matched PICO, for example: population=de novo kidney transplant recipients from 13 studies; intervention/exposure=CNI plus mTOR inhibitors; comparator=CNI plus antiproliferative agents; outcome=one named clinical endpoint. If mtor is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing animal model, human clinical/observational, and other source context.